Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Tax Provisions: 2023-2025

Historic Tax Provisions for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to -$3.2 million.

  • Monte Rosa Therapeutics' Tax Provisions fell 4574.65% to -$3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year increase of 158.85%. This contributed to the annual value of $2.6 million for FY2024, which is 669.23% up from last year.
  • Per Monte Rosa Therapeutics' latest filing, its Tax Provisions stood at -$3.2 million for Q3 2025, which was down 364.97% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' Tax Provisions ranged from a high of $2.2 million in Q4 2024 and a low of -$3.2 million during Q3 2025.
  • For the 3-year period, Monte Rosa Therapeutics' Tax Provisions averaged around $179,900, with its median value being $180,000 (2023).
  • In the last 5 years, Monte Rosa Therapeutics' Tax Provisions spiked by 10,072.73% in 2024 and then slumped by 4,574.65% in 2025.
  • Monte Rosa Therapeutics' Tax Provisions (Quarterly) stood at -$22,000 in 2023, then skyrocketed by 10,072.73% to $2.2 million in 2024, then plummeted by 4,574.65% to -$3.2 million in 2025.
  • Its Tax Provisions stands at -$3.2 million for Q3 2025, versus $1.2 million for Q2 2025 and $822,000 for Q1 2025.